Travere Therapeutics

OverviewSuggest Edit

Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam, and Thiola. The Company also has a number of product candidates to treat various serious diseases.
TypePublic
Founded2011
HQSan Diego, CA, US
Websitetravere.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Sept 2021)239(+9%)
Job Openings51
Revenue (FY, 2021)$227.5 M(+15%)
Share Price (Aug 2022)$25.8(+8%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Travere Therapeutics

Eric Dube

Eric Dube

President and Chief Executive Officer
Laura Clague

Laura Clague

Chief Financial Officer
Peter Heerma

Peter Heerma

Chief Commercial Officer
William Rote

William Rote

Senior Vice President of Research & Development
Jula Inrig

Jula Inrig

Chief Medical Officer
Elizabeth Reed

Elizabeth Reed

Senior Vice President, General Counsel, Corporate Secretary
Show more

Travere Therapeutics Office Locations

Travere Therapeutics has offices in San Diego and Dublin
San Diego, CA, US (HQ)
3721 Valley Centre Dr #200san
Dublin, IE
2nd Floor, Palmerston House, Fenian St
Show all (2)

Travere Therapeutics Financials and Metrics

Travere Therapeutics Revenue

Travere Therapeutics's revenue was reported to be $227.49 m in FY, 2021
USD

Revenue (Q1, 2022)

48.5m

Net income (Q1, 2022)

(76.0m)

EBIT (Q1, 2022)

(66.1m)

Market capitalization (4-Aug-2022)

1.5b

Closing stock price (4-Aug-2022)

25.8

Cash (31-Mar-2022)

256.6m
Travere Therapeutics's current market capitalization is $1.5 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

28.2m99.9m133.6m154.9m164.2m175.3m198.3m227.5m

Revenue growth, %

254%34%

Cost of goods sold

571.0k2.2m4.6m3.6m5.5m5.2m6.1m6.8m

Gross profit

27.6m97.7m129.0m151.3m158.7m170.1m192.2m
Quarterly
USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

27.9k5.7m8.3m17.4m24.1m29.0m33.3m33.9m33.6m38.8m40.3m38.4m41.3m40.7m39.6m44.7m44.4m47.8m48.4m51.1m47.4m54.6m54.2m48.5m

Cost of goods sold

900.01.2m197.4k274.4k637.0k513.0k757.0k1.0m1.6m709.0k797.0k925.0k1.6m1.2m1.1m1.0m979.0k1.5m1.5m1.2m1.6m1.7m2.1m

Gross profit

27.0k4.5m8.2m17.1m23.4m28.3m32.3m32.4m32.9m38.0m39.4m36.8m40.2m39.6m38.6m43.7m42.9m46.9m50.0m45.8m

Gross profit Margin, %

97%79%98%98%97%97%97%95%98%98%98%96%97%97%97%98%97%97%98%97%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

11.4k6.0m18.2m37.8m41.0m99.4m102.9m62.4m84.8m165.8m

Accounts Receivable

8.0m12.5m18.5m13.9m14.5m18.0m15.9m

Prepaid Expenses

1.4m813.4k2.4m3.1m2.3m5.0m8.1m6.5m

Inventories

800.5k2.5m2.8m5.4m5.6m6.1m7.6m7.3m
Show all financial metrics

Travere Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Travere Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Travere Therapeutics Online and Social Media Presence

Embed Graph

Travere Therapeutics News and Updates

Travere Therapeutics Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update.

Travere Therapeutics Provides Regulatory Updates on its Development Programs

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022

Travere Therapeutics to Report Second Quarter 2022 Financial Results

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the …

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomeru…

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT.
Show more

Travere Therapeutics Frequently Asked Questions

  • When was Travere Therapeutics founded?

    Travere Therapeutics was founded in 2011.

  • Who are Travere Therapeutics key executives?

    Travere Therapeutics's key executives are Eric Dube, Laura Clague and Peter Heerma.

  • How many employees does Travere Therapeutics have?

    Travere Therapeutics has 239 employees.

  • What is Travere Therapeutics revenue?

    Latest Travere Therapeutics annual revenue is $227.5 m.

  • What is Travere Therapeutics revenue per employee?

    Latest Travere Therapeutics revenue per employee is $951.8 k.

  • Who are Travere Therapeutics competitors?

    Competitors of Travere Therapeutics include Genexine, JCR Pharmaceuticals and Bath ASU.

  • Where is Travere Therapeutics headquarters?

    Travere Therapeutics headquarters is located at 3721 Valley Centre Dr #200san, San Diego.

  • Where are Travere Therapeutics offices?

    Travere Therapeutics has offices in San Diego and Dublin.

  • How many offices does Travere Therapeutics have?

    Travere Therapeutics has 2 offices.